Pibrentasvir

證據等級: L5

預測適應症: 10 個

Pibrentasvir: From Chronic Hepatitis C Virus Infection to Hepatitis B Virus Infection

One-Sentence Summary

Pibrentasvir is an NS5A inhibitor marketed only as part of the glecaprevir/pibrentasvir combination (Maviret/Mavyret) for chronic Hepatitis C virus (HCV) infection. The TxGNN model predicts it may be effective for Hepatitis B Virus Infection, with 14 clinical trials and 20 publications nominally attached to this candidate — but on inspection, every one of them studies HCV (or HCV co-infection), not HBV. This appears to be a label-confusion artifact rather than a genuine repurposing signal.

Quick Overview

Item	Content
Original Indication	Not available from Finland regulatory data (drug not marketed); per known pharmacology, pibrentasvir is a component of glecaprevir/pibrentasvir, used for chronic Hepatitis C virus (HCV) infection
Predicted New Indication	Hepatitis B Virus Infection
TxGNN Prediction Score	99.84%
Evidence Level	L4 (as labeled by the evidence pack — see caveat below)
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available in this evidence pack (flagged as a High-severity data gap). Based on known information, pibrentasvir is part of the glecaprevir/pibrentasvir fixed-dose combination, an NS5A protein inhibitor that binds the highly variable region of HCV NS5A. Its established efficacy is specifically against chronic HCV infection (genotypes 1–6).

The prediction that this profile extends to Hepatitis B does not hold up mechanistically. HBV belongs to the Hepadnaviridae family and replicates via reverse transcription and a cccDNA reservoir — a completely different biology from HCV's NS5A-dependent replication complex. There is no known HBV homolog of the HCV NS5A binding site, and no preclinical or clinical data in this evidence pack shows anti-HBV activity for pibrentasvir.

Reviewing the underlying evidence confirms this: all 14 clinical trials and 20 publications linked to this candidate involve HCV (including HCV/HBV or HCV/HIV co-infected populations), with sustained virologic response to HCV (SVR12) as the endpoint — not HBV DNA suppression or HBsAg clearance. Only one publication (PMID 29485084) even mentions HBV, and it addresses HBV vaccination after HCV treatment — a co-management topic, not a drug-efficacy signal. This pattern is consistent with a TxGNN embedding-space artifact confusing "viral hepatitis" concepts (HCV vs. HBV) rather than a real pharmacological relationship. The evidence pack's own rationale field reaches the same conclusion.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01995071	Phase 2	Completed	89	Dose-ranging safety/antiviral activity of ABT-493+ABT-530 in genotype 1 chronic HCV — not HBV
NCT02640157	Phase 3	Completed	506	ABT-493/ABT-530 vs. sofosbuvir+daclatasvir in genotype 3 HCV (ENDURANCE-3)
NCT03823911	Phase 4	Completed	87	Cardiovascular risk outcomes after HCV eradication in HIV/HCV co-infected patients
NCT02707952	Phase 3	Completed	295	G/P efficacy/safety in Japanese adults with chronic HCV (CERTAIN-1)
NCT03092375	Phase 3	Completed	177	G/P ± ribavirin in genotype 1 HCV patients previously treated with an NS5A inhibitor + sofosbuvir
NCT03219216	Phase 3	Completed	100	G/P in treatment-naïve Brazilian adults with HCV genotype 1–6
NCT02441283	Phase 2/3	Completed	384	Long-term follow-up of DAA resistance/durability of response in HCV patients
NCT02446717	Phase 2/3	Completed	141	G/P ± ribavirin in HCV patients who failed prior DAA therapy
NCT02243280	Phase 2	Completed	174	G/P ± ribavirin in HCV genotype 1, 4, 5, 6 (SURVEYOR-I)
NCT02640482	Phase 3	Completed	304	G/P vs. placebo in genotype 2 HCV (ENDURANCE-2)

None of the 14 registered trials for this candidate enroll HBV-infected patients or use an HBV endpoint.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31981264	2020	Cohort	J Viral Hepat	Real-world GLE/PIB effectiveness/safety in HCV patients with severe renal impairment (Taiwan)
31041789	2019	Cohort	Semin Liver Dis	Retreatment strategies for HCV patients who fail DAA therapy
35431505	2022	Cohort	World J Gastroenterol	Real-world DAA effectiveness in HIV/HCV genotype 6 co-infection
29485084	2018	Review	Lancet Infect Dis	HBV vaccination strategy after completing HCV treatment — a co-management topic, not evidence of anti-HBV drug activity
34298832	2021	Review	Cancers	Hepatocellular carcinoma in chronic kidney disease; general liver-cancer epidemiology, not HBV-specific drug evidence
30982721	2019	Not classified	Lancet Gastroenterol Hepatol	Overview of HCV infection in children/adolescents
34092970	2021	Not classified	World J Gastroenterol	Pediatric viral hepatitis management (HBV and HCV); discusses available DAAs for HCV, not HBV activity of pibrentasvir
35579223	2022	Not classified	Eur J Gen Pract	Primary-care overview of chronic HCV diagnosis and treatment
29369303	2018	Not classified	AIDS Rev	Conference report covering global HBV and HCV burden and elimination roadmap; not a drug-efficacy study
31114957	2019	Not classified	Clin Pharmacokinet	Pharmacokinetic/pharmacodynamic update on HCV DAA regimens including glecaprevir/pibrentasvir

None of the 20 publications report pibrentasvir activity against HBV.

Safety Considerations

Please refer to the package insert for safety information (TFDA/Fimea warnings, contraindications, and drug-interaction data are not available in this evidence pack).

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted HBV indication lacks any supporting mechanistic, preclinical, or clinical evidence — all 14 trials and 20 publications attached to this candidate concern HCV, not HBV, and the evidence pack's own rationale identifies this as a likely TxGNN label-confusion artifact between related "viral hepatitis" concepts rather than a real repurposing signal. Pibrentasvir is also not marketed in Finland, and core safety data (TFDA warnings/contraindications) is a Blocking-severity gap that independently prevents any S1 safety evaluation.

To proceed, the following is needed:

Confirmed mechanism-of-action data from DrugBank to formally rule out (or in) any HBV-relevant activity
TFDA/Fimea package insert (warnings, contraindications) to close the Blocking data gap
If this candidate is retained for tracking, a dedicated PubMed/ClinicalTrials.gov search specifically filtered for HBV (not general "viral hepatitis") to confirm the absence of genuine evidence
Given the consistent false-positive pattern across all 10 predicted indications for this drug (HBV, HIV, HEV, HAV, animal hepatitis, Omsk/Kyasanur fever, SIV, FIV, and an unrelated neurodevelopmental disorder), consider deprioritizing or excluding this drug-candidate pair from further repurposing review
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.